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Summary
Succinic semialdehyde dehydrogenase (SSADH) defi-
ciency, a rare metabolic disorder of 4-aminobutyric acid
degradation, has been identified in ∼150 patients. Af-
fected individuals accumulate large quantities of 4-hy-
droxybutyric acid, a compound with a wide range of
neuropharmacological activities, in physiological fluids.
As a first step in beginning an investigation of the mo-
lecular genetics of SSADH deficiency, we have utilized
SSADH cDNA and genomic sequences to identify two
point mutations in the SSADH genes derived from four
patients. These mutations, identified by standard meth-
ods of reverse transcription, PCR, dideoxy-chain ter-
mination, and cycle sequencing, alter highly conserved
sequences at intron/exon boundaries and prevent the
RNA-splicing apparatus from properly recognizing the
normal splice junction. Each family segregated a mu-
tation in a different splice site, resulting in exon skipping
and, in one case, a frameshift and premature termination
and, in the other case, an in-frame deletion in the re-
sulting protein. Family members, including parents and
siblings of these patients, were shown to be heterozy-
gotes for the splicing abnormality, providing additional
evidence for autosomal recessive inheritance. Our results
provide the first evidence that 4-hydroxybutyric acid-
uria, resulting from SSADH deficiency, is the result of
genetic defects in the human SSADH gene.
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Introduction
Succinic semialdehyde dehydrogenase (SSADH; E.C.
1.2.1.24 [MIM 271980]) deficiency is a defect in the 4-
aminobutyric acid (GABA) degradative pathway that re-
sults in the organic aciduria 4-hydroxybutyric aciduria
(Gibson et al. 1994) (fig. 1). The enzyme deficiency
causes not only an increase of the neurotransmitter
GABA but also significant accumulation of 4-hydroxy-
butyric acid (GHB) in physiological fluids, presumably
through the NAD(P)H-linked reduction of succinic sem-
ialdehyde by one or more GHB dehydrogenases (Cash
et al. 1979). These observations suggest that SSADH
deficiency is a unique disorder, since two neurophar-
macologically active compounds accumulate.
4-Hydroxybutyric aciduria was first reported in 1981
(Jakobs et al. 1981) in a child presenting with neuro-
logical abnormalities. Since then, ∼150 patients with
SSADH deficiency have been identified, with consider-
able variability in phenotype, ranging from mild retar-
dation in mental, motor, and language development to
more-severe neurological defects associated with hypo-
tonia, ataxia, and seizures (Gibson et al. 1997). Con-
sanguinity in many families and demonstration of in-
termediate enzyme activity in the parents of affected
patients suggest that SSADH deficiency is inherited in
an autosomal recessive fashion. Molecular cloning of the
human gene, as well as the mapping of it to chromosome
6p22 (Trettel et al. 1996), suggests that the mode of
inheritance for this disorder is autosomal recessive.
Tentative identification of SSADH deficiency is
achieved through detection of elevated levels of GHB in
physiological fluids (Jakobs et al. 1990). Verification of
the diagnosis is achieved by enzymatic assay of SSADH
in the patient lymphocytes, lymphoblasts, or fibroblasts
(Gibson et al. 1991, 1994), and prenatal diagnosis of 4-
hydroxybutyric aciduria has been reported in several
cases (Jakobs et al. 1993; Gibson et al. 1994). In affected
pregnancies, GHB is elevated in amniotic fluid, and
SSADH activity is absent from cultured amniocytes and,
400 Am. J. Hum. Genet. 63:399–408, 1998
Table 1
SSADH-Specific Primers for RT-PCR and Genomic PCR
Primer Sequence Orientation
1 TCTGGGCATGGTAGCCGACTG Forward
2 CTTTTCACAGAGTTTGCTGC Reverse
3 GCATCTAAATTTAGGAACACTGG Forward
4 CAAAGAATCCTACAAGCCCCC Reverse
5 CCTATATATGTAGATAAGTCTCC Reverse
6 CTGAGTTATAACGGGGAATGGT Forward
7 TGCACCTTCTCTTCTTCCCACA Reverse
8 GTAAATTGTTGGCACATGTTTG Forward
9 TGGTGATCAGGATGAAATAG Reverse
Figure 1 GABA degradative pathway. 1  GABA-transaminase; 2  SSADH; and 3  one or more 4-hydroxybutyrate dehydrogenases.
The cross-hatched box denotes the site of the defect in patients with SSADH deficiency.
in one case, from autopsied fetal brain, liver, and kidney
(Chambliss et al. 1993).
Although it is highly likely that defects in the SSADH
gene are the cause of SSADH deficiency, thus far there
has been no evidence to support this hypothesis. Re-
cently, we reported cDNAs encoding rat and partial hu-
man SSADH (Chambliss et al. 1995). Cosmid clones
were employed to localize the gene to human chromo-
some 6p22 (Trettel et al. 1996). An extremely high GC
content in the 5′ end of the human SSADH transcript
prohibited isolation of full-length human cDNA clones.
In the present article, we have used recently obtained
genomic cosmid clones to derive the remainder of the
cDNA structure of human SSADH, including the pu-
tative mitochondrial leader sequence. A composite hu-
man cDNA expresses enzymatically active SSADH pro-
tein. We also report, in four patients (two families), two
mutations in the SSADH gene that lead to exon skipping,
and we document that these mutant alleles exist at the
cDNA and genomic level. These alleles have been labeled
“ALDH4A1*1” (GrT transversion, first base of intron
9) and “ALDH4A1*2” (GrA transition, first base of
intron 5), according to the nomenclature proposed by
Nebert and coworkers (Vasiliou et al., in press). In the
consanguineous matings, inheritance was confirmed by
allele analysis in family members. These exon-skipping
mutations result in near-complete absence of SSADH
activity, representing the first demonstration that struc-
tural defects in the SSADH gene can be the cause of
SSADH deficiency (4-hydroxybutyric aciduria).
Material and Methods
Lymphoblastoid Cell Lines and Enzyme Assay
Lymphocytes isolated from blood samples of patients,
family members, and controls were used to assay SSADH
activity, as has been reported elsewhere (Gibson et al.
1991), as well as to establish lymphoblastoid cell lines
by standard procedures using Epstein-Barr virus. Cells
were grown, maintained, and assayed as reported else-
where (Gibson et al. 1997). The four patients studied
were from consanguineous marriages, and clinical find-
ings have been reported in earlier articles (Haan et al.
1985; Gibson et al. 1997).
Nucleic-Acid Isolation, Amplification, and Sequencing
DNA and total RNA were isolated from lymphoblast
cell lines by means of established procedures (Chambliss
et al. 1995). Reverse transcription (RT) of ∼10 mg of
total RNA was performed at 42C for 1 h, by means of
Moloney murine leukemia virus (MMLV) reverse tran-
scriptase (Gibco BRL) with a gene-specific antisense pri-
mer (primer 5; table 1). Subsequent PCR amplification
was performed with Expand High Fidelity thermostable
polymerase (BoehringerMannheim), either with an exon
6 forward primer (primer 3) and exon 10 reverse primer
(primer 4), to examine exon 9 deletions, or with an exon
1 forward primer (primer 1) and an exon 6 reverse prim-
er (primer 2), to examine exon 5 deletions (for exon
structure, see fig. 2).
For amplification of exon 9 from genomic DNA, 100
ng of genomic DNA from lymphoblast cell lines was
used in PCR amplifications using primers 6 and 7. Prim-
ers 8 and 9 were used to amplify exon 5 and its flanking
regions. Amplification products were excised from aga-
rose gels and were purified by means of the Qiaex II gel-
extraction kit (Qiagen). Direct sequencing of purified
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Figure 2 Nucleotide and deduced amino acid sequence of human SSADH. Nucleotides and amino acid residues are numbered to the
right, with the first residue of the mature protein being boxed and numbered as “1.” The positions of the nine introns that split the coding
region were determined by comparison of cDNA and genomic clones and are indicated by vertical lines. This sequence has been deposited in
GenBank (accession number Y11192).
products was performed by means of Thermo Sequenase
DNA polymerase and Redivue [33P]-labeled terminators
(Amersham).
An intermediate product of the amplification of RNAs
from individuals heterozygous for the exon 5 deletion
was shown to be produced during PCR reactions in
which both wild-type and exon 5–deletion templates
were present and independent of any cellular RNA. The
wild-type and exon 5–deficient RT-PCR products were
purified extensively by multiple agarose gels and sub-
sequent Qiaex purification. Individual amplification of
purified wild-type or exon 5–deficient PCR products
yielded a single product identical to the starting tem-
plate; however, simultaneous amplification of the two
templates produced not only the two starting templates
but also an intermediate product, seen in the heterozy-
gotes (data not shown); this suggests that this PCR prod-
uct, intermediate between the wild-type and exon 5–de-
ficient amplicons, is due to heteroduplex formation due
to reannealing of one strand containing exon 5 and one
strand deficient in exon 5.
Expression of Recombinant Human SSADH
The human SSADH-expression clone was constructed
by first subcloning the most full-length cDNA (GenBank
accession number R20294; I.M.A.G.E. consortium,
Lawrence Livermore National Laboratory) (Lennon et
al. 1996) into the bacterial-expression vector pGEX-4T3
(Pharmacia). This construct lacked the DNA region en-
coding the first 21 amino acid residues of the mature
protein. A segment from an SSADH genomic subclone
encoding the additional 21 residues plus 47 amino acid
residues of the putative mitochondrial targeting se-
quence was ligated into the proper position of the ex-
pression clone by means of XmaCI and NotI restriction
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sites. Bacterial-cell lines, growth conditions, and enzy-
matic assay of bacterial extracts were those used in pro-
tocols reported elsewhere (Chambliss et al. 1995).
Results
Completion and Expression of the Human SSADH
cDNA
We recently isolated and characterized a 1,091-bp
human liver SSADH cDNA that encoded ∼66% of the
mature human SSADH protein (Chambliss et al. 1995).
A search of the GenBank database revealed three
additional expressed sequence tag (EST) cDNAs
(R20294, H06675, and H46643; I.M.A.G.E. consor-
tium, L.L.N.L) (Lennon et al. 1996) that overlapped the
partial human SSADH cDNA and that extended the se-
quence farther upstream, to include all but the N-ter-
minal 21 amino acids of the mature human protein (fig.
2). The remainder of the human SSADH cDNA coding
region can be inferred from human SSADH genomic
cosmid clones from chromosome 6 (Trettel et al. 1996).
The genomic clones contain sequences that overlap the
most full-length cDNAs and extend through the mature
N-terminus coding region, which was verified by amino
acid sequencing of the purified protein (Chambliss et al.
1995). The genomic clones also extended beyond the
putative start codon 47 amino acid residues upstream
of the mature N-terminus. Several observations suggest
that this AUG is the translation-initiation site. First,
there is a single AUG codon in reasonable proximity to
(and in the proper reading frame with) the mature N-
terminus; the next closest AUG is 477 bp upstream from
the mature N-terminus and has two stop codons shortly
downstream. Second, this AUG is within a Kozak con-
sensus translational start motif (Kozak 1991). Last, the
47 amino acids from the N-terminal methionine to the
mature N-terminus are recognized, by computer analysis
(PROSITE), as a mitochondrial targeting sequence with
a predicted cleavage site exactly at the point of the ma-
ture N-terminus (Gavel and von Heijne 1990).
Despite these largely confirmatory observations, we
cannot exclude the possibility that there is another intron
somewhere within this region, since it is relatively com-
mon for some or most of a leader peptide to be on an
independent exon. Thus far, multiple attempts at RT-
PCR and RACE, with a wide variety of primer pairs
derived from genomic DNA sequence, have been un-
successful in producing a PCR product from this region
to verify that it is indeed within the cDNA sequence.
This most likely relates to the extremely high GC con-
tent and probable secondary structure within this region.
Once a PCR product is obtained, it will be of value to
investigate precursor translocation and proteolytic-pro-
cessing in isolated mitochondria, in addition to trans-
fection into patient lymphoblasts.
As a first step in verification that the isolated sequence
is human SSADH, a composite construct was made,
which encoded the full-length human SSADH protein
(with putative leader) fused to glutathione-S-transferase.
Bacterial extracts overexpressing the protein were as-
sayed for SSADH activity, with the following results: rat
composite cDNA (without leader), 1,345–1,390 nmol/
min/mg protein; human expression clone (with putative
mitochondrial leader), 60–65 nmol/min/mg protein; and
expression vector only, 15–18 nmol/min/mg protein (in
each case, the results are those of two independent ex-
pression studies). Although the recombinant human en-
zyme was considerably less active (22-fold less) than re-
combinant rat SSADH, the human protein had
significant SSADH activity, compared with that in con-
trols expressing glutathione-S-transferase only. It is un-
clear why the human enzyme was less active than the
rat enzyme; however, comparable results were obtained
during purification of SSADH from human brain and
rat brain. In those studies, the final specific activity of
purified rat-brain SSADH was 21.39 mmol/min/mg pro-
tein, whereas that for the human brain enzyme was 2.74
mmol/min/mg protein (Chambliss and Gibson 1992). Al-
though the presence of the mitochondrial targeting se-
quence in the recombinant fusion protein may have neg-
atively impacted enzyme activity, the recombinant fusion
protein still had four times the background activity, in-
dicating that we indeed were measuring SSADH activity.
Mutation of the SSADH Gene in Four Patients
Knowledge of the entire coding region of human
SSADH enabled us to examine the gene of patients with
4-hydroxybutyric aciduria, for the presence of possible
molecular defects. Four previously reported patients
from two families, along with available family members,
were investigated. The patients were two siblings, OD
and PD, and their cousin, ZZ, from one family and a
single child, patient AC, from a second, unrelated family
(Haan et al. 1985; Jakobs et al. 1993). All patients were
from consanguineous matings, with ZZ and AC being
from a first-cousin marriage and with OD and PD being
from a second-cousin marriage. SSADH enzyme activi-
ties in extracts of cells from one of the families (three
patients and their family members) are presented in table
2. Residual activity in patient cells was very low and, in
most cases, nearly undetectable. Intermediate activities
were observed in parents’ and siblings’ cell lines. Enzyme
activities for both patient AC and his parents have been
reported elsewhere and are consistent with those re-
ported here for members of the family of patients OD
and PD. The very low SSADH activities in extracts of
cells from members of the family of patient ZZ are in-
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Table 2
SSADH Enzyme Activities of SSADH-Deficient Patients and
Their Family Members
Cell Type and Subjecta
SSADH Specific Activityb
(nmol/min/mg protein)
Lymphoblasts:c
Family of ZZ:
ZZ 0 [0%]
Father .09 [8%]
Mother .18 [16%]
Male sibling .11 [10%]
Female sibling .11 [10%]
Controls for family ( )n  5 1.15  .27 [NA]
Family of OD and PD:
OD .013 [1%]
PD .022 [1%]
Father 1.467 [79%]
Mother 1.247 [67%]
Sibling (male) .836 [45%]
Controls for family ( )n  4 1.85  .43 [NA]
Lymphocytes:
Family of OD and PD:
OD .015 [7%]
PD .000 [0%]
Father .107 [53%]
Mother .065 [32%]
Sibling (male) .099 [49%]
Controls for family ( )n  5 .20  .06 [NA]
a Patients ZZ, OD, and PD are related (Jakobs et al. 1990).
b Percentages are percentage of control values; NA  not ap-
plicable. Control values are the average of assays from four or five
parallel control cell lines.
c Analyses of patient ZZ and of patients OD and PD were per-
formed on separate occasions.
triguing, since they were considerably below both the
values expected in heterozygotes and the values detected
in members of the family of patients OD and PD (who
carry an identical mutation). Unfortunately, additional
members of the family of patient ZZ (i.e., individuals
who did not harbor the splicing defect and could be
assayed for SSADH activity in lymphoblasts) were not
available; lymphoblasts from these individuals would be
more appropriate as controls than are random lympho-
blasts from unrelated, unaffected individuals. The data
suggest the possibility that another gene (or gene prod-
uct) affects SSADH activity and is different between
these two families, although, at present, there are no
data to support this possibility.
We performed RT followed by PCR (RT-PCR) anal-
ysis of RNA isolated from lymphoblasts of the afore-
mentioned SSADH-deficient patients (ZZ, OD, and PD),
their parents and siblings, and two unrelated SSADH-
deficient patients (SM and IA). Analysis of the RT-PCR
products on agarose gels revealed shortened amplicons
for all patients except SM and IA, compared with those
in controls (figs. 3 and 4). Direct sequencing of the am-
plicons in OD, PD, and ZZ revealed an exact deletion
of the 59-bp exon 9 (Trettel et al. 1996) (fig. 5). The
parents of OD and PD and the parents of ZZ were
heterozygous for the exon 9 deletion, as were a male
and female sibling of ZZ and a male sibling of OD and
PD. All controls and unrelated patients were homozy-
gous for the presence of exon 9. The net effect of the
missing exon is a frameshift after amino acid residue
401 (of a total of 488 amino acids in the mature protein),
followed by 52 nonsense residues before a stop codon
is reached. Of the missing 87 amino acid residues, 26
are conserved between human, rat, and bacterial SSADH
(Chambliss et al. 1995). Of these 26 residues, 11 are
highly conserved among many aldehyde and semialde-
hyde dehydrogenases, from mammals to bacteria, in-
cluding 6 invariant residues at N413, G441, N446,
G459, S463, and G466 (Hempel et al. 1993; Chambliss
et al. 1995).
Examination of the genomic region surrounding exon
9 was performed to determine why the exon sequence
was missing in the cDNA. Intron-specific primers on
either side of exon 9 were employed in PCR amplifi-
cations using genomic DNA isolated from the lympho-
blasts of patients OD, PD, and ZZ, of their family mem-
bers, and of controls. All samples yielded the expected
471-bp product. Direct sequencing of the products re-
vealed that exon 9 sequence was present in all individ-
uals tested; however, patients OD, PD, and ZZ were
homozygous for a GrT transversion at the first base of
intron 9 in the splice-donor site (fig. 6). The parents and
siblings of these patients proved to be heterozygous for
the transversion, a finding that was consistent both with
the RT-PCR results and the enzymatic assay; none of
the controls exhibited the base change. Thus, the three
patients in this family are homozygous for an SSADH
allele that leads to a splicing defect (skipping of exon
9), whereas the unaffected parents and siblings are het-
erozygous for this allele.
Direct sequencing of the single RT-PCR product from
patient AC (fig. 4) revealed an exact deletion of the 144-
bp exon 5 (fig. 7). In RT-PCR, the parents of AC ex-
hibited four amplified products. The top two bands are
present in control samples. The more prominent of these
two bands—the lower band (632 bp)—displayed wild-
type sequence on direct sequencing, whereas the less in-
tense of the two bands—the upper band—was a mixture
of sequences containing wild-type SSADH and another,
unidentified sequence. This upper band appears to be a
PCR artifact. The smallest RT-PCR product (488 bp) in
the parents proved to be the same 144-bp deletion of
exon 5 as was seen in the patient. Direct sequencing of
the RT-PCR product intermediate between the wild-type
DNA band and exon 5–deficient DNA band shows a
mixture of sequences consistent with both the wild-type
product and the exon 5–deficient product. Further ex-
perimentation (seeMaterial andMethods) indicated that
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Figure 3 RT-PCR products from five patients with 4-hydroxybutyric aciduria, their family members, and a control, analyzed on an
ethidium bromide–stained agarose gel. The amplicon from a normal SSADH cDNA is 638 bp. Three of the patients exhibit a visibly smaller
product, whereas their parents and unaffected siblings have both RT-PCR products, indicating heterozygosity. Two unrelated patients have the
wild-type–size amplicon. Lane M, Molecular-weight size standards. Lane 1, Control. Lane 2, Patient ZZ. Lane 3, Father of ZZ. Lane 4, Mother
of ZZ. Lane 5, Brother of ZZ. Lane 6, Sister of ZZ. Lane 7, Patient OD. Lane 8, Patient DP (sister of OD). Lane 9, Father of OD and PD;
Lane 10, Mother of OD and PD. Lane 11, Brother of OD and PD. Lane 12, Unrelated patient SM. Lane 13, SM mother. Lane 14, Unrelated
patient IA.
Figure 4 RT-PCR products from patient AC (lane 3), his parents
(lanes 1 and 2), and a control (lane 4), analyzed on an agarose gel.
Lane M, Size standards. The dominant product obtained from the
control sample is 632 bp, whereas the single product from PCRs of
the patient is 144 bp smaller (i.e., 488 bp). The intermediate-size prod-
uct was shown to be artifactual and independent of RNA template.
this product was an artifact most likely due to hetero-
duplex formation between strands with or without exon
5 sequence. The result of the exon 5 deletion is an in-
frame excision of 48 amino acid residues (196–242), 17
of which are conserved between human, rat, and bac-
terial SSADH (Chambliss et al. 1995); 11 of these 17
residues are highly conserved among other mammalian
and bacterial aldehyde dehydrogenases with the two in-
variant glycines G237 and G242 (Hempel et al. 1993).
Examination of the genomic DNA sequence around
exon 5 was performed by PCR amplification using gene-
specific intron primers flanking exon 5 (fig. 8). The se-
quence of patient AC revealed a GrA transition at the
first base of intron 5 in the splice-donor site, whereas
the parents were heterozygous for this base change.
These findings are consistent both with RT-PCR results
and with the results of previously reported enzymatic
assays. Thus, the patient in this family is homozygous
for an SSADH allele that leads to the skipping of exon
5, whereas the healthy parents are heterozygous for the
allele.
The remaining coding regions of patients OD, PD,
ZZ, and AC were amplified by RT-PCR, sequenced, and
shown to have no changes from the published wild-type
sequence. Additionally, to examine the possibility that
one or both of these mutations may be common in other
SSADH-deficient patients, genomic DNA from lympho-
blasts of 11 individuals with SSADH deficiency in 10
families, from 9 family members from 3 of the families,
and from 5 control cell lines was used to amplify the
regions around exons 5 and 9, and the amplification
products were sequenced. Neither of these mutations
was observed in any other patients or controls (data not
shown).
Discussion
We have characterized human SSADH cDNAs and
have completed the identification of the regions encoding
the putative mitochondrial leader sequence and mature
protein, as a first step in beginning an investigation of
the molecular genetics of SSADH deficiency. Recombi-
nant human protein encoded by a composite cDNA
clone and expressed in Escherichia coli was shown to
have SSADH activity. By using the SSADH cDNA and
genomic sequence, we have identified, in the SSADH
genes of four patients, two point mutations that alter
the highly conserved sequences at intron/exon bound-
aries and that prevent the RNA splicing apparatus from
properly recognizing the normal splice junction. The re-
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Figure 5 DNA sequence of representative RT-PCR products from the gel in figure 3. The larger band consistently contained the wild-
type SSADH cDNA sequence, whereas the smaller amplicon consistently exhibited a complete deletion of the 59-bp exon 9.
Figure 6 Representative DNA sequence of PCR products amplified from genomic DNA of wild-type controls (left), patients (center), and
family members of patients (right). The three patients, (ZZ, OD, and PD) all contained a GrT mutation at the first base of intron 9, which
alters the 5′ splice site. Family members of patients who exhibited both RT-PCR products proved to be heterozygous for this mutation.
sulting RNA splicing errors result in both SSADH de-
ficiency, as demonstrated by enzymatic assay of patient
lymphocytes and lymphoblasts, and 4-hydroxybutyric
aciduria, as established by previous biochemical inves-
tigations of patient blood and urine. Our results provide
the first demonstration of genetic defects in the SSADH
gene that lead to SSADH deficiency, and they confirm
the autosomal recessive nature of the disorder.
It has been estimated that, of all genetic diseases
caused by point mutations, 15% are in RNA consensus
splice sites (Krawczak et al. 1992). Mutations at the first
base of an intron at the invariant G of the splice-donor
site are involved in the majority of 5′ splice-site muta-
tions. The most common mutation at this position is a
GrA transition, which was observed in patient AC.
Other genetic disorders documented to have been caused
by a GrA change at the same site include retinoblas-
toma, acute porphyria, phenylketonuria, Ehlers-Danlos
syndrome VII and IV, and many others (Krawczak et al.
1992). Although not as frequently reported, GrT trans-
versions, as seen in patients OD, PD, and ZZ, also have
been documented in a number of genetic diseases, in-
cluding androgen insensitivity, cystic fibrosis, hemo-
philia B, and retinoblastoma (Krawczak et al. 1992). In
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Figure 7 DNA sequence of representative RT-PCR products from the gel in figure 4. All lower bands were missing the 144-bp exon 5,
whereas the predominant upper band contained wild-type sequence. The less predominant upper band and the intermediate band were shown
to be PCR artifacts (see text).
Figure 8 Genomic DNA sequence around exon 5 in controls (left), patient AC (center), and patient AC’s parents (right), examined by
PCR. The single, 271-bp amplicon was directly sequenced. The patient was homozygous for a GrA base change at the first base of intron 5.
His parents were heterozygous for the normal G at that position and the mutant A. Controls showed wild-type sequence.
the aforementioned disorders, the consensus 5′ splice-
site mutations lead to a skipping of the exon preceding
the mutation, as seen in both mutations in the present
report, and/or to the utilization of a cryptic splice site
somewhere within the intron.
SSADH is clearly a member of the aldehyde dehy-
drogenase superfamily, sharing 36%–38% homology to
mammalian general aldehyde dehydrogenases. Compar-
ison of SSADH with other aldehyde and semialdehyde
dehydrogenases, in both prokaryotes and eukaryotes,
reveals amino acid residues with important enzymatic
function, as evidenced by their strict conservation (Hem-
pel et al. 1993; Chambliss et al. 1995). The exons miss-
ing in patients described in the present report remove
several of these key—and, in some cases, invari-
ant—residues. The ideal situation in which to examine
the effects of such changes on the enzyme activity is
represented by the lymphoblast cell lines derived from
the homozygous patients. These patients represent an in
vivo system in which only the mutant form of SSADH
is produced. It is apparent that these mutations abolish
SSADH activity. Further corroboration of the effects of
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the mutations is obtained in the patients’ heterozygous
parents and siblings, who have intermediate activity,
compared with the homozygous mutant patients and the
unaffected controls.
The clinical phenotype of 4-hydroxybutyric aciduria
varies from mild to severe and is nonspecific in presenta-
tion. Most patients exhibit some degree of neurological
deficit, although speech delay, hypotonia, ataxia, and
seizures vary from patient to patient, even within the
same family. The patients in the present study are mod-
erately affected, exhibiting developmental and speech
delays, hyporeflexia, and behavioral problems, including
mild autism. Patients AC, OD, and PD exhibit hypo-
tonia, and patients OD and PD manifest ataxia. Patient
ZZ is the first of only two reported cases of 4-hydrox-
ybutyric aciduria in an adult and was 23 years of age
at the time of examination, in 1990. At the initial presen-
tation, all patients had increased GHB in blood and
urine. For all patients, including those in the present
study, residual SSADH activity measured in extracts of
cultured cells is !5% of control values.
Thus far, correlation between either GHB levels or
residual SSADH activity and clinical symptoms has not
been demonstrated. Similar levels of GHB in patient
physiological fluids have been seen in both mildly and
severely affected patients. One previously reported pa-
tient (Gibson et al. 1997) presented with only mild oc-
ulomotor problems, truncal ataxia, and no other major
neurological sequelae, and this patient already has de-
veloped a vocabulary that is nearly age appropriate.
Ironically, this patient has almost no residual enzyme
activity. Other patients, with comparable levels of resid-
ual enzyme activity, have suffered a devastating clinical
course, with severe psychomotor retardation leading to
a persistent vegetative state (DeVivo et al. 1988).
Whether this heterogeneity is the result of mutation se-
verity, tissue expression and/or penetrance, modifier
genes, environmental influences, or other factors remains
to be determined. However, a first step in trying to un-
ravel this phenotypic heterogeneity is a careful analysis
of the molecular genetics of SSADH deficiency.
The prevalence of SSADH deficiency in the general
population is not known and is difficult to estimate.
Patients are identified only when primary-care physi-
cians or metabolic specialists submit samples to labo-
ratories that analyze organic-acid patterns. The major
difficulty is the nonspecific phenotypic presentation of
SSADH deficiency, and many patients have received a
differential diagnosis of autism, fragile-X syndrome, or
idiopathic mental retardation. We suggest that many pa-
tients presenting in neurology clinics are undiagnosed
because organic-acid analysis is not requested. Addi-
tionally, GHB in urine is an unstable compound that
could be missed if laboratory staff who analyze organic
acids are inexperienced. Assuming that, because spe-
cialized assays are required, SSADH deficiency is only
rarely detected and noting that the number of patients
identified (∼150) is relatively large, we could speculate
that the disorder would occur as frequently as some of
the other rare metabolic disorders, such as medium-
chain acyl-CoA dehydrogenase deficiency, the frequency
of which has been estimated to be 1/6,400–1/46,000,
with 1%–2% of the population estimated to be heter-
ozygous for a disease-causing allele (Roe and Coates
1995).
Once 4-hydroxybutyric aciduria is diagnosed on the
basis of organic-acid profiling, a common treatment is
use of the antiepileptic vigabatrin (gamma-vinyl GABA;
Sabril) (Gibson et al. 1995). Pharmacologically, the
mode of action of this drug is an irreversible inhibition
of GABA-transaminase, leading to accumulation of free
and total GABA in brain. The results of this therapy
have been encouraging in some patients and of little
value in others. Patients for whom vigabatrin has shown
clinical efficacy had improvement in ataxia (when pre-
sent), increased alertness, improved attention span, and
better manageability. Other patients had no improve-
ment in clinical signs, and at least two patients experi-
enced seizures during vigabatrin intervention (Gibson et
al. 1989; Matern et al. 1996). There is an obvious need
for better therapeutic agents for treatment of SSADH-
deficient patients. We are currently pursuing the pro-
duction of a murine transgenic model of the disease,
which will be of great use in examination of other cur-
rently available drugs that may provide better therapeu-
tic efficacy.
Carrier screening of the general population for
SSADH deficiency is currently impossible and unfeasible.
Although lymphocyte SSADH activity of heterozygous
individuals is generally intermediate between that in pa-
tients and that in controls, the range of carrier enzyme
activity overlaps both patient and control values. It is
not yet known whether there will be a wide variety of
mutations in the SSADH gene or whether shared alleles
will be found to account for a high percentage of pa-
tients. As the genetic defects in other documented pa-
tients are identified, it may become possible to use mo-
lecular tests to screen high-risk populations (i.e., those
in which there is a high incidence of consanguineous
marriages), for the presence of shared disease-causing
alleles. To achieve this, we will need to have as complete
a picture as possible of the molecular abnormalities re-
sponsible for SSADH deficiency; these studies are in
progress.
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